Results 251 to 260 of about 86,395 (301)
Some of the next articles are maybe not open access.
2006
Publisher Summary This chapter provides an overview of Antifungal drugs. In comparison with bacteria or viruses, fungi are more complex organisms. They have ribosomes, cellular membrane components, and a nuclear membrane. Therefore, antibacterial antibiotics are, as a rule, ineffective against pathogenic fungi.
Victor J. Hruby, Ruben Vardanyan
openaire +3 more sources
Publisher Summary This chapter provides an overview of Antifungal drugs. In comparison with bacteria or viruses, fungi are more complex organisms. They have ribosomes, cellular membrane components, and a nuclear membrane. Therefore, antibacterial antibiotics are, as a rule, ineffective against pathogenic fungi.
Victor J. Hruby, Ruben Vardanyan
openaire +3 more sources
The Lancet, 2003
The echinocandins are large lipopeptide molecules that are inhibitors of beta-(1,3)-glucan synthesis, an action that damages fungal cell walls. In vitro and in vivo, the echinocandins are rapidly fungicidal against most Candida spp and fungistatic against Aspergillus spp.
openaire +4 more sources
The echinocandins are large lipopeptide molecules that are inhibitors of beta-(1,3)-glucan synthesis, an action that damages fungal cell walls. In vitro and in vivo, the echinocandins are rapidly fungicidal against most Candida spp and fungistatic against Aspergillus spp.
openaire +4 more sources
Antifungals and antifungal drug discovery.
2012Abstract This chapter discusses: (1) important clinical aspects of invasive clinical mycoses, i.e., candidosis and aspergillosis; (2) current antifungal therapeutic options for invasive mycoses; (3) antifungal drug resistance; and (4) approaches to antifungal drug discovery, including identification of drug targets.
A. Tegos +8 more
openaire +2 more sources
The Antifungal Drug Clotrimazole
Acta Crystallographica Section C Crystal Structure Communications, 1998AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
Hye-Rim Shin, Hyun Song
openaire +4 more sources
Current Opinion in Microbiology, 1999
There have been many new developments in antifungal therapy in the past few years. Some antifungal drugs have been reformulated to reduce toxicity (e.g. new lipid formulations of polyenes), and new derivatives of drugs have been developed to enhance potencies.
openaire +2 more sources
There have been many new developments in antifungal therapy in the past few years. Some antifungal drugs have been reformulated to reduce toxicity (e.g. new lipid formulations of polyenes), and new derivatives of drugs have been developed to enhance potencies.
openaire +2 more sources
1992
The allylammes constitute a recently developed class of synthetic antimycotics characterized functionally by their action as squalene epoxidase inhibitors.1 Figure 6–1 shows the structures of three representative allylamines. Naftifine, the first of these compounds to be discovered, was first synthesized in 1974,2 and its antifungal properties were ...
Neil S. Ryder, Hubert Mieth
openaire +3 more sources
The allylammes constitute a recently developed class of synthetic antimycotics characterized functionally by their action as squalene epoxidase inhibitors.1 Figure 6–1 shows the structures of three representative allylamines. Naftifine, the first of these compounds to be discovered, was first synthesized in 1974,2 and its antifungal properties were ...
Neil S. Ryder, Hubert Mieth
openaire +3 more sources
Antifungal Drug Resistance in Aspergillus
Journal of Infection, 2000This article overviews the emerging problem of antifungaldrug resistance in Aspergillus. Fluconazole and ketocona-zole (KCZ) are inactive against Aspergillus. Validation oftesting procedures for the detection of itraconazole (ITZ)resistance in Aspergillus fumigatusin 19971,2were furthervalidated with posaconazole (SCH-56592)3,4and voricona-zole (VCZ)5 ...
J. Mosquera +5 more
openaire +4 more sources
Antifungal drugs on the horizon
Journal of the American Academy of Dermatology, 1994In the past 10 years there has been a major expansion in the development of antifungal drugs, but there are still weaknesses in the range and scope of current antifungal chemotherapy. New developments have included the modification of existing drug molecules to eliminate toxicity and improve activity, for instance, the development of the lipid ...
openaire +3 more sources
Pediatrics In Review, 2016
1. Lynn Smitherman, MD* 1. *Wayne State University School of Medicine, Detroit, MI. 1. 1. Tay E. Azole Antifungal Agents. Tay E. Pediatr Rev. 2005;26(1):20–21 [OpenUrl][1][FREE Full Text][2] 2. 1. Jura S, 2. Hillenbrand K. Fluconazole. Jura S, Hillenbrand K. Pediatr Rev. 2006;27(4):158–159 [OpenUrl][3]
openaire +3 more sources
1. Lynn Smitherman, MD* 1. *Wayne State University School of Medicine, Detroit, MI. 1. 1. Tay E. Azole Antifungal Agents. Tay E. Pediatr Rev. 2005;26(1):20–21 [OpenUrl][1][FREE Full Text][2] 2. 1. Jura S, 2. Hillenbrand K. Fluconazole. Jura S, Hillenbrand K. Pediatr Rev. 2006;27(4):158–159 [OpenUrl][3]
openaire +3 more sources
Antifungal Drugs and Resistance
1995From the late 1950’s, extending for two decades thereafter, amphotericin B was the only broad spectrum antifungal drug which could be systemically administered. Because it was the only option, and because systemic mycoses were relatively infrequent, there was little interest in understanding the mechanism of action of amphotericin B, or expanding ...
openaire +3 more sources